HeyJaredMegan Brooks
- Indexed articles, last 90 days
- 48
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 10, 2026
Latest articles
Few Women Consistently Use Endocrine Therapy Post-Lumpectomy (opens the original)
Read excerpt
Many women who undergo lumpectomy for early-stage breast cancer do not adhere to endocrine therapy long term, and those who skip radiotherapy may be a particularly vulnerable group. An analysis of insurance claims found that less than 30% of patients consistently adhered to endocrine therapy throughout all 5 recommended years. And two groups were especially likely to have substantial lapses in adherence: patients younger than 60 years and those who did not receive radiotherapy post-surgery. The
SRS Emerges as Option for SCLC Brain Mets (opens the original)
Read excerpt
Stereotactic radiosurgery (SRS) may offer an alternative to hippocampal-avoidant whole-brain radiotherapy (WBRT) for brain metastases from small cell lung cancer (SCLC), according to the first randomized phase 3 trial to compare the approaches. The NRG-CC009 trial yielded two unexpected findings: SRS did not improve patients’ cognitive outcomes compared with WBRT plus memantine, the trial’s primary endpoint. However, it was associated with a nearly 9-month gain in overall survival, according to
Shorter Prostate RT Holds Up at 5 Years, With Caveats (opens the original)
Read excerpt
A shorter course of radiotherapy (RT) after prostatectomy provides similar disease control and patient-reported outcomes as conventional fractionation at 5 years — but with a higher rate of physician-reported genitourinary (GU) toxicity, according to results from the phase 3 NRG-GU003 trial. The findings extend earlier 2-year results supporting hypofractionated postprostatectomy radiotherapy (HYPORT) as an alternative to conventionally fractionated postprostatectomy radiotherapy (COPORT), while
Alcohol-Related Cancer Deaths Rise as Cancer Deaths Fall (opens the original)
Read excerpt
Although cancer mortality has declined in the US over the past three decades, a large observational trend analysis found the opposite overall trend for alcohol-attributable cancer mortality. The research team estimated that, between 1990 and 2023, the number of cancer deaths attributed to alcohol more than doubled from 11,361 to 23,126. After accounting for population size and age, the alcohol-attributable cancer mortality rate increased by nearly 8%. “Our study adds a long-term, population-leve
HINTS for Dizziness: Who Should and Should Not Get Tested? (opens the original)
Read excerpt
The head impulse, nystagmus, test of skew (HINTS) exam should be reserved for patients with acute persistent dizziness who have nystagmus at rest — and only after screening for neurologic features suggesting a central cause, according to a new review aimed at reducing misuse of the bedside test and missed strokes. HINTS is a widely recognized bedside tool for distinguishing peripheral vestibular disorders from central causes, such as stroke, in patients presenting with acute vestibular syndrome.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.